Susanne Gertsson

Sr Clinical Project Manager at BioInvent International

Susanne Gertsson has a diverse work experience spanning over several industries. Susanne started their career as a Registered Nurse in the Intensive Care Unit at Ystad Hospital in 1985. Susanne then transitioned into the pharmaceutical sector, initially working as a Product Specialist at Parke Davis from 1993 to 1998. Following this role, they joined Pfizer as a Senior Clinical Research Associate (CRA) and worked there for eight years until 2006. During this time, they gained experience in clinical research and monitoring. Subsequently, they joined PRA International as a Senior CRA from 2006 to 2009 and then moved to ICON plc as a Senior CRA from 2009 to 2011. Susanne further advanced their career at Bristol-Myers Squibb, where they served as a Senior CRA from 2011 to 2018. Most recently, they joined BioInvent International AB in 2019 as a Senior Clinical Project Manager. Susanne's expertise lies in project management, clinical trials, and clinical research.

Susanne Gertsson's education history begins in 1982 when they attended Lunds Högskola and obtained a Bachelor's degree in Registered Nursing/Registered Nurse, which they completed in 1984. Following this, they pursued further education at Växjö Högskola, where they obtained another Bachelor's degree in intensive care nursing, which they completed in 1989. In 2014, Susanne attended Apotekarsocieteten and obtained a Swedish Diploma in Clinical Trials (Diplomering i klinisk prövning). Most recently, in 2020, they enrolled in a Certificate Program in Clinical Trial Project Management at Physis Global Academy.

Location

Ystad, Sweden

Links

Previous companies


Org chart

This person is not in the org chart


Teams


Offices

This person is not in any offices


BioInvent International

BioInvent International AB (Nasdaq Stockholm: BINV) is a clinical-stage biotech company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently three drug candidates in four ongoing clinical programs in Phase l/ll trials for the treatment of hematological cancer and solid tumors, respectively.


Industries

Headquarters

Lund, Sweden

Employees

51-200

Links